Quite impressive for a biotech company to get two oral presentations onto the AHA program (the other two presentations seem to be posters). What's very interesting is that both are of direct relevance to covid - suppression of ACE2 receptors and suppression of hyperactivation of monocytes (considered to be the likely culprits of a cytokine storm). Don has been very quiet on the covid front since the early excitement, but perhaps a clinical trial really is on the cards.